JAVELIN renal 101: a randomized, phase III study of avelumab + axitinib vs sunitinib as first-line treatment of advanced renal cell carcinoma (aRCC)

R. J. Motzer; K. Penkov; J. B. A. G. Haanen; B. I. Rini; L. Albiges; M. T. Campbell; C. K. Kollmannsberger; S. Negrier; M. Uemura; J. L. Lee; H. Gurney; R. Berger; M. Schmidinger; J. Larkin; M. B. Atkins; J. Wang; P. B. Robbins; A. Chudnovsky; A. Di Pietro; T. K. Choueiri

doi:10.1093/annonc/mdy424.036

JAVELIN renal 101: a randomized, phase III study of avelumab + axitinib vs sunitinib as first-line treatment of advanced renal cell carcinoma (aRCC)

R. J. Motzer, K. Penkov, J. B. A. G. Haanen, B. I. Rini, L. Albiges, M. T. Campbell, C. K. Kollmannsberger, S. Negrier, M. Uemura, J. L. Lee, H. Gurney, R. Berger, M. Schmidinger, J. Larkin, M. B. Atkins, J. Wang, P. B. Robbins, A. Chudnovsky, A. Di Pietro, T. K. Choueiri

Faculty of Medicine, Health and Human Sciences

Research output: Contribution to journal › Meeting abstract › peer-review

33 Citations (Scopus)

58 Downloads (Pure)

Original language	English
Pages (from-to)	viii724
Number of pages	1
Journal	Annals of Oncology
Volume	29
Issue number	Supplement 8
DOIs	https://doi.org/10.1093/annonc/mdy424.036
Publication status	Published - 1 Oct 2018
Event	43rd European Society for Medical Oncology Congress (ESMO 2018) - Munich, Germany Duration: 19 Oct 2018 → 23 Oct 2018

Bibliographical note

Version archived for private and non-commercial use with the permission of the author/s and according to publisher conditions. For further rights please contact the publisher.

Access to Document

10.1093/annonc/mdy424.036

Publisher version (open access)Final published version, 119 KBLicence: CC BY-NC-ND

Cite this

Motzer, R. J., Penkov, K., Haanen, J. B. A. G., Rini, B. I., Albiges, L., Campbell, M. T., Kollmannsberger, C. K., Negrier, S., Uemura, M., Lee, J. L., Gurney, H., Berger, R., Schmidinger, M., Larkin, J., Atkins, M. B., Wang, J., Robbins, P. B., Chudnovsky, A., Di Pietro, A., & Choueiri, T. K. (2018). JAVELIN renal 101: a randomized, phase III study of avelumab + axitinib vs sunitinib as first-line treatment of advanced renal cell carcinoma (aRCC). Annals of Oncology, 29(Supplement 8), viii724. https://doi.org/10.1093/annonc/mdy424.036

Motzer, R. J. ; Penkov, K. ; Haanen, J. B. A. G. ; Rini, B. I. ; Albiges, L. ; Campbell, M. T. ; Kollmannsberger, C. K. ; Negrier, S. ; Uemura, M. ; Lee, J. L. ; Gurney, H. ; Berger, R. ; Schmidinger, M. ; Larkin, J. ; Atkins, M. B. ; Wang, J. ; Robbins, P. B. ; Chudnovsky, A. ; Di Pietro, A. ; Choueiri, T. K. / JAVELIN renal 101 : a randomized, phase III study of avelumab + axitinib vs sunitinib as first-line treatment of advanced renal cell carcinoma (aRCC). In: Annals of Oncology. 2018 ; Vol. 29, No. Supplement 8. pp. viii724.

@article{384fac86689847d18b1d2755536709c8,

title = "JAVELIN renal 101: a randomized, phase III study of avelumab + axitinib vs sunitinib as first-line treatment of advanced renal cell carcinoma (aRCC)",

author = "Motzer, {R. J.} and K. Penkov and Haanen, {J. B. A. G.} and Rini, {B. I.} and L. Albiges and Campbell, {M. T.} and Kollmannsberger, {C. K.} and S. Negrier and M. Uemura and Lee, {J. L.} and H. Gurney and R. Berger and M. Schmidinger and J. Larkin and Atkins, {M. B.} and J. Wang and Robbins, {P. B.} and A. Chudnovsky and {Di Pietro}, A. and Choueiri, {T. K.}",

note = "Version archived for private and non-commercial use with the permission of the author/s and according to publisher conditions. For further rights please contact the publisher.; 43rd European Society for Medical Oncology Congress (ESMO 2018) ; Conference date: 19-10-2018 Through 23-10-2018",

year = "2018",

month = oct,

day = "1",

doi = "10.1093/annonc/mdy424.036",

language = "English",

volume = "29",

pages = "viii724",

journal = "Annals of Oncology",

issn = "0923-7534",

publisher = "OXFORD UNIV PRESS INC",

number = "Supplement 8",

}

Motzer, RJ, Penkov, K, Haanen, JBAG, Rini, BI, Albiges, L, Campbell, MT, Kollmannsberger, CK, Negrier, S, Uemura, M, Lee, JL, Gurney, H, Berger, R, Schmidinger, M, Larkin, J, Atkins, MB, Wang, J, Robbins, PB, Chudnovsky, A, Di Pietro, A & Choueiri, TK 2018, 'JAVELIN renal 101: a randomized, phase III study of avelumab + axitinib vs sunitinib as first-line treatment of advanced renal cell carcinoma (aRCC)', Annals of Oncology, vol. 29, no. Supplement 8, pp. viii724. https://doi.org/10.1093/annonc/mdy424.036

JAVELIN renal 101 : a randomized, phase III study of avelumab + axitinib vs sunitinib as first-line treatment of advanced renal cell carcinoma (aRCC). / Motzer, R. J.; Penkov, K.; Haanen, J. B. A. G.; Rini, B. I.; Albiges, L.; Campbell, M. T.; Kollmannsberger, C. K.; Negrier, S.; Uemura, M.; Lee, J. L.; Gurney, H.; Berger, R.; Schmidinger, M.; Larkin, J.; Atkins, M. B.; Wang, J.; Robbins, P. B.; Chudnovsky, A.; Di Pietro, A.; Choueiri, T. K.

In: Annals of Oncology, Vol. 29, No. Supplement 8, 01.10.2018, p. viii724.

Research output: Contribution to journal › Meeting abstract › peer-review

TY - JOUR

T1 - JAVELIN renal 101

T2 - 43rd European Society for Medical Oncology Congress (ESMO 2018)

AU - Motzer, R. J.

AU - Penkov, K.

AU - Haanen, J. B. A. G.

AU - Rini, B. I.

AU - Albiges, L.

AU - Campbell, M. T.

AU - Kollmannsberger, C. K.

AU - Negrier, S.

AU - Uemura, M.

AU - Lee, J. L.

AU - Gurney, H.

AU - Berger, R.

AU - Schmidinger, M.

AU - Larkin, J.

AU - Atkins, M. B.

AU - Wang, J.

AU - Robbins, P. B.

AU - Chudnovsky, A.

AU - Di Pietro, A.

AU - Choueiri, T. K.

N1 - Version archived for private and non-commercial use with the permission of the author/s and according to publisher conditions. For further rights please contact the publisher.

PY - 2018/10/1

Y1 - 2018/10/1

U2 - 10.1093/annonc/mdy424.036

DO - 10.1093/annonc/mdy424.036

M3 - Meeting abstract

C2 - 32137998

VL - 29

SP - viii724

JO - Annals of Oncology

JF - Annals of Oncology

SN - 0923-7534

IS - Supplement 8

Y2 - 19 October 2018 through 23 October 2018

ER -